Testing alpha-1 antitrypsin for severe alcohol-related liver inflammation
Part of Digestive system clinical trials.
This study tests whether giving a protein called alpha-1 antitrypsin can help people with severe liver inflammation caused by heavy drinking. It may reduce the damage and improve recovery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a severe form of alcohol-related liver inflammation, confirmed by a special calculation called Maddrey's score (32 or higher).
- You must not have acute-on-chronic liver failure, or only a mild grade of it.
- You must not be in the intensive care unit at the time of screening.
- You must have been drinking heavily (more than 6 drinks a day for men, or 4 for women) on average during the past 3 months.
- For women who could become pregnant: must have a negative pregnancy test, not be breastfeeding, and agree to use birth control. For men: must agree to use condoms and not donate sperm during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of treatments for people with severe alcohol-related liver disease (alcoholic hepatitis) that has not responded to standard care. The goal is to improve liver function and help you stop drinking.
This study looks at how alpha-1 antitrypsin deficiency affects the liver in adults. It aims to learn more about the liver problems caused by this condition and may help find better ways to manage them.
This study tests an investigational medicine called efimosfermin alfa to see if it is safe and effective for people with liver damage caused by heavy drinking. The medicine is compared to a placebo (a dummy treatment).
This trial tests a new medicine called larsucosterol to see if it helps people with severe alcohol-related hepatitis (liver inflammation from heavy drinking). If you qualify, the study will monitor your safety and recovery over 90 days.
This study tests an experimental RNA-based medicine (AIR-001) for people with a genetic form of alpha-1 antitrypsin deficiency (AATD). It aims to see if the drug can help boost your body's own protective protein levels and may slow lung damage.
This trial tests a new medicine called MRG-001 for people with severe alcoholic hepatitis, a liver condition caused by heavy drinking. The study aims to see if the drug can help improve liver function and reduce symptoms.
Hear when a new Alcohol-Associated Hepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.